Printer Friendly

Sirnaomics Oncology wins US FDA's approval to initiate study of STP705 in cholangiocarcinoma patients.

Global Banking News-August 17, 2018-Sirnaomics Oncology wins US FDA's approval to initiate study of STP705 in cholangiocarcinoma patients

(C)2018 ENPublishing - http://www.enpublishing.co.uk

Biopharmaceutical company Sirnaomics Inc disclosed on Thursday the receipt of approval from the US Food and Drug Administration (FDA) to launch the study of its first oncology IND lead product candidate, STP705, in patients with advanced cholangiocarcinoma (CCA).

Cholangiocarcinoma (CCA) is the second most common hepatic primary malignancy (accounting for 15-20% of liver cancer). CCA is also known as bile duct adenocarcinoma and biliary tract cancer.

According to the company, STP705 is an anti-cancer/anti-fibrosis siRNA (small interfering RNA) therapeutic. It takes advantage of a dual-targeted inhibitory property and a proprietary polypeptide nanoparticle (PNP)-enhanced delivery system to target cells in the liver. It acts by directly inhibiting tumorigenesis through down regulation of Cancer Associated Fibroblast (CAF) activity and cell proliferation by silencing both TGF-?1 and COX-2 gene expression within the tumor micro-environment.

The company said STP705 is composed of two siRNA oligonucleotides, targeting TGF-?1 and COX-2 mRNA and formulated in nanoparticles with Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA was demonstrated to inhibit the expression of their target mRNAs and combining the two siRNA's produces a synergistic effect that diminishes pro-fibrogenic and pro-inflammatory factors. Additional data suggests reductions in TGF-?1 and COX-2 led to proapoptotic effects in fibroblasts.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:Aug 17, 2018
Words:236
Previous Article:Eisai Inc and Merck passes US FDA's approval for LENVIMA for the treatment of patients with unresectable hepatocellular carcinoma.
Next Article:The US FDA approves first generic EpiPen for the emergency treatment of allergic reactions.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters